Business Description
Dianthus Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US2528281080
Total Employee Number:
92Description
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 814.71 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 68.06 | |||||
Beneish M-Score | 0.11 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -50.3 | |||||
3-Year EBITDA Growth Rate | -32.1 | |||||
3-Year EPS without NRI Growth Rate | -29.7 | |||||
3-Year FCF Growth Rate | -19.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -8.06 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 60.45 | |||||
9-Day RSI | 62.56 | |||||
14-Day RSI | 60.58 | |||||
3-1 Month Momentum % | -2 | |||||
6-1 Month Momentum % | 117.46 | |||||
12-1 Month Momentum % | 374.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 29.25 | |||||
Quick Ratio | 29.25 | |||||
Cash Ratio | 29.03 | |||||
Days Sales Outstanding | 400.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -42.9 | |||||
Shareholder Yield % | -14.29 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -14318.04 | |||||
Net Margin % | -12998.5 | |||||
EBITDA Margin % | -14290.27 | |||||
FCF Margin % | -9764.69 | |||||
OCF Margin % | -9749.78 | |||||
ROE % | -30.22 | |||||
ROA % | -28.66 | |||||
ROIC % | -164.09 | |||||
3-Year ROIIC % | -114.95 | |||||
ROC (Joel Greenblatt) % | -12085.48 | |||||
ROCE % | -32.98 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 3043.23 | |||||
PB Ratio | 4.29 | |||||
Price-to-Tangible-Book | 4.29 | |||||
EV-to-EBIT | -21.16 | |||||
EV-to-EBITDA | -21.2 | |||||
EV-to-Revenue | 3029.43 | |||||
EV-to-Forward-Revenue | 2480.73 | |||||
EV-to-FCF | -31.02 | |||||
Price-to-GF-Value | 32.41 | |||||
| Price-to-Net-Current-Asset-Value | 4.79 | |||||
| Price-to-Net-Cash | 4.83 | |||||
Earnings Yield (Greenblatt) % | -4.73 | |||||
FCF Yield % | -2.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dianthus Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.147 | ||
| EPS (TTM) (€) | -3.545 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 70.45 | ||
| 14-Day RSI | 60.58 | ||
| 14-Day ATR (€) | 3.309068 | ||
| 20-Day SMA (€) | 75.425 | ||
| 12-1 Month Momentum % | 374.19 | ||
| 52-Week Range (€) | 15.4 - 85.5 | ||
| Shares Outstanding (Mil) | 54.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dianthus Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dianthus Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 123 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 33 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 14:40 | 73.00 (+4.29%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 12:45 | 74.50 (-1.97%) | ||
| General meeting for 2026 | 2026-05-21 09:00 | 76.00 (+2.70%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 75.50 (+2.03%) | ||
| Dianthus Therapeutics, Inc Interim Responder Analysis Results of the Phase 3 Captivate Trial | 2026-03-09 08:00 | 56.00 (+6.67%) | ||
| Annual report for 2025 | 2026-03-09 | 56.00 (+6.67%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-09 | 56.00 (+6.67%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 13:50 | 46.80 (+1.74%) |
Show
Entries
Dianthus Therapeutics Inc Frequently Asked Questions
What is Dianthus Therapeutics Inc(STU:87E)'s stock price today?
The current price of STU:87E is €82.00. The 52 week high of STU:87E is €85.50 and 52 week low is €15.40.
When is next earnings date of Dianthus Therapeutics Inc(STU:87E)?
The next earnings date of Dianthus Therapeutics Inc(STU:87E) is 2026-08-07 Est..
Does Dianthus Therapeutics Inc(STU:87E) pay dividends? If so, how much?
Dianthus Therapeutics Inc(STU:87E) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Dianthus Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers